The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | Inferior outcomes seen in elderly patients with HL
Jonathan Friedberg, MD, University of Rochester, Rochester, NY, explores why elderly patients with Hodgkin lymphoma (HL) demonstrate inferior outcomes, including comorbidities that limit the ability to give standard treatment, as well as the complex form of Hodgkin lymphoma seen in older patients. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
